Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

PURPOSE: Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-toler...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Richardson, Paul G., Weller, Edie, Jagannath, Sundar, Avigan, David E., Alsina, Melissa, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Ghobrial, Irene M., Doss, Deborah, Warren, Diane L., Lunde, Laura E., McKenney, Mary, Delaney, Carol, Mitsiades, Constantine S., Hideshima, Teru, Dalton, William, Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2009
主題:
Original Reports
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799050/
https://ncbi.nlm.nih.gov/pubmed/19786667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.2679
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍